Tvardi Q2 2026 net loss $6.5M; TTI-109 to target UC after positive healthy-volunteer data

Tvardi Therapeutics, Inc.

Net loss $6.5M vs net income $4.2M in Q2 2025 (prior year had $12.7M non-cash gain); EPS -$0.69.
TTI-109 healthy-volunteer topline confirms prodrug design, improved tolerability, and immune-cell reductions.
Selected ulcerative colitis (UC) as first TTI-109 indication; >1.25M US patients, ~$3B US market.
Cash $15.8M at June 30, 2026, down from $30.8M; funds operations through HCC readout into Q3 2027.
Upcoming: KOL webinar Aug 19, 2026; TTI-101 HCC data 4Q 2026; UC trial start 2027 subject to IND/funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.